Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zevra Therapeutics, Inc. - Common Stock (NQ:ZVRA)

7.160 +0.110 (+1.56%)
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zevra Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Earnings Scheduled For March 11, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock
Via Benzinga
Zevra Therapeutics Mixed Q2 Results: Details
Zevra Therapeutics reported its second-quarter financial results Tuesday. Here's a look at the details. 
Via Benzinga
Zevra Therapeutics: Q4 Earnings Insights
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... 
Via Benzinga
Exposures Product Safety
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Earnings Outlook For Zevra Therapeutics
Via Benzinga
Zevra Therapeutics's Earnings: A Preview
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q2 2024
ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
PubMatic, Eventbrite, Five9 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases
FDA panel supports Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C with an 11-5 vote. William Blair boosts success probability to 90%, highlighting Zevra's growth and balanced rare... 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Insiders Buying Zevra Therapeutics And 1 Other Stock
Via Benzinga
Insiders Buying Barnes & Noble Education And 2 Other Stocks
Via Benzinga
SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL
Via AB Newswire
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. 
Via Benzinga
Exposures Product Safety
ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024
ZVRA stock results show that Zevra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Letter to Stakeholders Looks Like Launch Code to Drive Value
Via Investor Brand Network
ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA)
From Kirby McInerney LLP
Via GlobeNewswire
ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023
ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
BioMedNewsBreaks – Zevra Therapeutics Inc. (NASDAQ: ZVRA) Resubmits Arimoclomol New Drug Application to the FDA
Via Investor Brand Network
Exposures Product Safety
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. 
Via Benzinga
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.